Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer
- PMID: 27555767
- PMCID: PMC4968984
- DOI: 10.2147/IJN.S105420
Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer
Abstract
Cabazitaxel-loaded human serum albumin nanoparticles (Cbz-NPs) were synthesized to overcome vehicle-related toxicity of current clinical formulation of the drug based on Tween-80 (Cbz-Tween). A salting-out method was used for NP synthesis that avoids the use of chlorinated organic solvent and is simpler compared to the methods based on emulsion-solvent evaporation. Cbz-NPs had a narrow particle size distribution, suitable drug loading content (4.9%), and superior blood biocompatibility based on in vitro hemolysis assay. Blood circulation, tumor uptake, and antitumor activity of Cbz-NPs were assessed in prostatic cancer xenograft-bearing nude mice. Cbz-NPs exhibited prolonged blood circulation and greater accumulation of Cbz in tumors along with reduced toxicity compared to Cbz-Tween. Moreover, hematoxylin and eosin histopathological staining of organs revealed consistent results. The levels of blood urea nitrogen and serum creatinine in drug-treated mice showed that Cbz-NPs were less toxic than Cbz-Tween to the kidneys. In conclusion, Cbz-NPs provide a promising therapeutic for prostate cancer.
Keywords: cabazitaxel; drug delivery; human serum albumin; nanoparticle; prostate cancer; toxicity.
Figures






Similar articles
-
Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer.Int J Nanomedicine. 2020 Jul 29;15:5333-5344. doi: 10.2147/IJN.S258856. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32801692 Free PMC article.
-
Preparation and Evaluation of in vitro Self-assembling HSA Nanoparticles for Cabazitaxel.Anticancer Agents Med Chem. 2017;17(2):294-300. doi: 10.2174/1871520616666160526103102. Anticancer Agents Med Chem. 2017. PMID: 27225451
-
Human Serum Albumin Nanoparticles as a Novel Delivery System for Cabazitaxel.Anticancer Res. 2016 Apr;36(4):1649-56. Anticancer Res. 2016. PMID: 27069142
-
Albumin Nanocarriers, γ- Irradiated Crosslinked, Combined with Therapeutic Drugs for Cancer Therapy>Curr Pharm Des. 2017;23(35):5272-5282. doi: 10.2174/1381612823666170615105909. Curr Pharm Des. 2017. PMID: 28619004 Review.
-
A critical review of lipid-based nanoparticles for taxane delivery.Cancer Lett. 2013 Jul 1;334(2):157-75. doi: 10.1016/j.canlet.2012.07.006. Epub 2012 Jul 13. Cancer Lett. 2013. PMID: 22796606 Free PMC article. Review.
Cited by
-
Thiophene Derivatives as Anticancer Agents and Their Delivery to Tumor Cells Using Albumin Nanoparticles.Molecules. 2019 Jan 6;24(1):192. doi: 10.3390/molecules24010192. Molecules. 2019. PMID: 30621360 Free PMC article.
-
Novel Selectively Targeted Multifunctional Nanostructured Lipid Carriers for Prostate Cancer Treatment.Pharmaceutics. 2021 Dec 30;14(1):88. doi: 10.3390/pharmaceutics14010088. Pharmaceutics. 2021. PMID: 35056984 Free PMC article.
-
Topical Drug Delivery of Concentrated Cabazitaxel in an α-Tocopherol and DMSO Solution.Adv Sci (Weinh). 2023 Oct;10(29):e2302658. doi: 10.1002/advs.202302658. Epub 2023 Aug 9. Adv Sci (Weinh). 2023. PMID: 37555802 Free PMC article.
-
Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel.Cancers (Basel). 2019 Oct 16;11(10):1571. doi: 10.3390/cancers11101571. Cancers (Basel). 2019. PMID: 31623082 Free PMC article.
-
Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy.Acta Biomater. 2020 Sep 1;113:501-511. doi: 10.1016/j.actbio.2020.06.019. Epub 2020 Jun 18. Acta Biomater. 2020. PMID: 32562805 Free PMC article.
References
-
- Mellado B, Jimenez N, Marin-Aguilera M, Reig O. Diving into cabazitaxel mode of action; more than a taxane for the treatment of castration resistance prostate cancer patients. Clin Genitourin Cancer. 2015 Dec 28; Epub. - PubMed
-
- Zhuang B, Du L, Xu H, et al. Self-assembled micelle loading cabazitaxel for therapy of lung cancer. Int J Pharm. 2016;499(1–2):146–155. - PubMed
-
- Moriceau G, Guillot A, Pacaut C, et al. Translating clinical evidence-based medicine into the real world: single-center experience with cabazitaxel in metastatic prostate cancer patients. Chemotherapy. 2016;61(3):127–133. - PubMed
-
- Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95(6):593–599. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous